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INTRODUCTION OBJECTIVE
RESULTS SAMMSON knock	down	using	LNA	antisense	oligonucleotides	reduces	cell	viability	and	induces	cell	apoptosis
Combining	SAMMSON inhibition	and	MAPK	inhibition	results	in	
a	synergistic	decrease	in	cell	viability
CONCLUSION FUTURE	DIRECTIVES
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Fig. 1 Sustained upregulation of
SAMMSON lncRNA expression
in skin melanoma (SKCM) and
uveal melanoma (UVM)
compared to other cancer
types
SAMMSON inhibition	as	monotherapy	and	in	combination	with	MEK	inhibition	reduces	tumor	growth	
in	vivo	
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Fig. 2 LNA-based ASO3 and ASO11 treatment result in a knock down of SAMMSON expression in conjunctival melanoma
cell line CRMM1 (A) and uveal melanoma cell lines OMM2.3 and 92.1 (B, C).
Fig. 3 LNA-based ASO3 and ASO11 reduce the cell viability (A) and induce apoptosis (B) in multiple uveal
melanoma and conjunctival melanoma cell lines, independent of the mutational status of the cell line.
II SAMMSON knock	down	results	in	a	decreased	mitochondrial	respiration
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Fig. 4 Two independent methods to investigate mitochondrial function show a decreased mitochondrial respiration upon SAMMSON knock
down. ASO3 treatment results in an overall decreased oxygen consumption rate (OCR) (A) and significant decreased spare mitochondrial
capacity (A,B). Fluorescence imaging of mitochondria demonstrates a decreased electric membrane potential (∆Ψ) upon ASO3 and ASO11
treatment (C).
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o Most	common	eye	tumor	in	adults
o Primary	treatment:	Sx or	Rx
o Metastatic	disease	à survival	time	<	12	months
o No	treatment	for	metastatic	disease
o Melanoma	specific	lncRNA	SAMMSON
o SAMMSON knockdown	results	in
o Reduction	in	cell	viability	and	induction	of	apoptosis
o Decreased	mitochondrial	respiration
o Decreased	tumor	volume	in	vivo
o SAMMSON inhibition	synergizes	with	MEK	inhibition
o Identification	of	SAMMSON interaction	partners
o Validation	of	the	observed	phenotype	using	alternative	ASOs	
o Combination	therapy	of	SAMMSON inhibition	with	PKC	inhibitors
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- Vehicle	+	NTC	(n=9)
- Vehicle	+	ASO3	(n=8)
- Trametinib	+	NTC	(n=8)
- Trametinib	+	ASO3	(n=8)
Fig. 6 SAMMSON inhibition (ASO3) as a monotherapy inhibits tumor growth. Combining ASO3 with MEK inhibitor trametinib results in a
further decrease of the tumor growth.
Fig. 5 SAMMSON inhibition (ASO3) in combination with increasing concentrations of the MEK
inhibitor trametinib results in a synergistic decrease in viability in uveal melanoma cell line 92.1
(A) and conjunctival melanoma cell line CRMM1 (B). Drug interaction was calculated using BLISS
independence score. E-values < 0 indicate synergism.
A B
o Validation	of	the	therapeutic	effects	of	SAMMSON inhibition	in	
uveal	melanoma	
o Evaluation	of	the	effects	of	SAMMSON inhibition	on	mitochondrial	
respiration
o Validation	of	combination	therapy	including	SAMMSON inhibition	
and	MEK	inhibition
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